Výsledky vyhledávání - "Puhlmann, M."

The ECHELON-2 Trial:5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Publikováno v: Horwitz, S, O'Connor, O A, Pro, B, Trümper, L, Iyer, S, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Menne, T, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A, Hüttmann, A, Savage, K J, Yuen, S, Zinzani, P L, Miao, H, Bunn, V, Fenton, K, Fanale, M, Puhlmann, M & Illidge, T 2022, ' The ECHELON-2 Trial : 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma ', Annals of Oncology, vol. 33, no. 3, pp. 288-298 . https://doi.org/10.1016/j.annonc.2021.12.002
Horwitz, S, O'Connor, O A, Pro, B, Trümper, L, Iyer, S, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Menne, T, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A, Hüttmann, A, Savage, K J, Yuen, S, Zinzani, P L, Miao, H, Bunn, V, Fenton, K, Fanale, M, Puhlmann, M & Illidge, T 2021, ' The ECHELON-2 Trial : 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 3, pp. 288-298 . https://doi.org/10.1016/j.annonc.2021.12.002

BACKGROUND: For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy are typically poor. The ECHELON-2 study demonstrated that

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b3bfa6d1173b5676a4c251f8a185f45
https://findresearcher.sdu.dk:8443/ws/files/199229320/1_s2.0_S0923753421048754_main.pdf

Zobrazit plný text záznamu

Akademický článek

Modelling the carbon budget of intensive forest monitoring sites in Germany using the simulation model BIOME-BGC

Autor: Jochheim H, Puhlmann M, Beese F, Berthold D, Einert P, Kallweit R, Konopatzky A, Meesenburg H, Meiwes K-J, Raspe S, Schulte-Bisping H, Schulz C

Publikováno v: iForest - Biogeosciences and Forestry, Vol 2, Iss 1, Pp 7-10 (2009)

It is shown that by calibrating the simulation model BIOME-BGC with mandatory and optional Level II data, within the ICP Forest programme, a well-founded calculation of the carbon budget of forest stands is achievable and, based on succeeded calibrat

Externí odkaz: https://doaj.org/article/194a5ba5a66e4c179553c275dd59cb8c

Zobrazit plný text záznamu

ECHELON-2 (NCT01777152), A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN plus CHP VS CHOP IN PREVIOUSLY UNTREATED PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA: 5-YEAR RESULTS

Publikováno v: Zinzani, P L, Illidge, T, Horwitz, S M, O'Connor, O A, Pro, B, Iyer, S P, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T A, Menne, T, Belada, D, Illes, A, Tobinai, K, Tsukasaki, K, Yeh, S-P, Huttmann, A, Savage, K J, Yuen, S, Miao, H, Bunn, V, Fenton, K, Fanale, M A, Puhlmann, M & Trumper, L 2021, ' ECHELON-2 (NCT01777152), A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN plus CHP VS CHOP IN PREVIOUSLY UNTREATED PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA: 5-YEAR RESULTS ', Haematologica, vol. 106, no. 10, Suppl. 3, pp. 3 . < https://doi.org/10.3324/haematol.2021.s3 >

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::f0965bd430d8c8753ef8c4c900cf6c95
https://portal.findresearcher.sdu.dk/da/publications/d13b2c46-5c6b-482c-b508-9f2b755dfe65

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání